Mutagenicity of <i>N</i> -nitroso-fluoxetine and <i>N</i> -nitroso-varenicline in human HepaRG cell models
J.H. Seo(National Center for Toxicological Research), Aisar Atrakchi(Center for Drug Evaluation and Research), Karen L Davis Bruno(Center for Drug Evaluation and Research), Jaime A. Miranda(National Center for Toxicological Research), David A. Keire(Center for Drug Evaluation and Research), Robert H. Heflich(National Center for Toxicological Research), Timothy J. McGovern(Center for Drug Evaluation and Research), Javier R. Revollo(National Center for Toxicological Research)
Cited by 1
Related Papers
The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells
|Journal of Biological Chemistry|2004|994
Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
|Cell Metabolism|2007|899
The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals
|Current Opinion in Gastroenterology|2007|310
Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme
|Nature Structural & Molecular Biology|2006|295
Mechanisms Generating Diversity in Glucocorticoid Receptor Signaling
|Annals of the New York Academy of Sciences|2009|219